Documents

Record quarterly growth driven by CDMO and Affordable Medicines, with margins and CapEx rising.

Strong financials, strategic growth, and robust governance drive future confidence.

FY 2026 saw 23% revenue growth and margin expansion, led by CDMO and generics strength.

Strong Q3 growth driven by generics, CDMO, and ARV, with stable margins and high CapEx.

Q2 revenue up 35% YoY, margins expanded, and CapEx drives growth in ARV and CDMO segments.

Q1 saw 31% revenue growth, margin gains, and strong CDMO momentum, with robust outlook.

Strong FY2025 growth with expanding CDMO, stable ARV, and margin improvement expected in FY2026.

Strong Q3 growth driven by CDMO and formulations, with strategic investments fueling future expansion.

Flat revenue, strong CDMO growth, and margin improvement expected in H2 FY25.

Q1 FY25 revenue grew modestly YoY, but net profit declined; new Independent Director appointed.